COMP <GO>
DLB vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
Dolby Laboratories (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: DLB 11
— TMO 3
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: DLB
LAST: $61.99 (-1.46%) • MKT CAP: $5.89B
balance-sheet
8.20
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DLB VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DLB | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.10% | 41.00% | +47.10 | DLB | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.50% | 9.30% | +0.20 | DLB | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.6x | 30.4x | -11.80 | DLB | /valuation <GO> |
| Free Cash Flow Yield | 7.40% | 2.40% | +5.00 | DLB | /fcf-yield <GO> |
| Operating Margin | 19.60% | 17.40% | +2.20 | DLB | /operating-margins <GO> |
| Net Profit Margin | 18.90% | 15.10% | +3.80 | DLB | /net-margins <GO> |
| Revenue Growth (YoY) | 5.90% | 3.90% | +2.00 | DLB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.15% | 0.24% | +1.91 | DLB | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 8.20 | 4.50 | +3.70 | DLB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.70% | +0.20 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.6 | 59.1 | -3.53 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 0.94 | +0.06 | DLB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.5x | 36.3x | -14.80 | DLB | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.89B | $262.22B | -$256.32B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DLB REV | TMO REV | DLB GROSS % | TMO GROSS % | DLB FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.35B | $44.56B | 88.1% | 44.0% | $435.9M | $6.29B |
| FY 2024 | $1.27B | $42.88B | 89.0% | 44.0% | $297.2M | $7.27B |
| FY 2023 | $1.30B | $42.86B | 44.0% | 44.0% | $308.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DLB // BETA 1.00
TMO // BETA 0.94